Even if the GLP-1 agonist delay in gastric emptying does not impact many of the medications we use, I have seen numerous patients complain of nausea and vomiting while on these drugs
If you are specifically interested in peptide-based approaches to body composition, treatments like AOD-9604 or GLP-1 agonists like semaglutide and tirzepatide work through fundamentally different pathways
Low-fat versus ketogenic diet in Parkinsons disease: a pilot randomized controlled trial
It is applied to the places where the fat mass is most in the body: abdomen, stomach, buttocks, top of the buttocks, both sides of the waist, hips, inner thighs and knees, back, male breast enlargement (gynecomastia), for slight excesses in the arm and chin (under the chin)